AFC
ALNY icon

Ares Financial Consulting’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ares Financial Consulting’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.32K Buy
21
+1
+5% +$302 ﹤0.01% 661
2026
Q1 		$6.58K Hold
20
– – 0.01% 632
2025
Q4 		$7.95K Buy
+20
New +$8.85K 0.01% 393

Other funds holding ALNY

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Ares Financial Consulting's ALNY Position: Q2 2026 in Review

Ares Financial Consulting increased its Alnylam Pharmaceuticals (ALNY) stake by 5% in Q2 2026, buying an estimated $302 and bringing the position to 21 shares worth $6.32K. The position accounts for ﹤0.01% of the portfolio, ranked #661.

Ares Financial Consulting first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.95K in Q4 2025. 330 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Ares Financial Consulting held 21 shares of Alnylam Pharmaceuticals worth $6.32K as of Q2 2026.
  • Ares Financial Consulting bought 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #661 holding.
  • Ares Financial Consulting first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Ares Financial Consulting's Alnylam Pharmaceuticals position peaked at $7.95K in Q4 2025.
  • 330 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.